drugset
drugset / Trial / NCT06785454

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454 ↗

Phase 2 Completed 48 enrolled Mineralys Therapeutics Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.

Timeline

Start
2025-02-28
Primary completion
2025-12-17
Completion
2025-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject lorundrostat Small molecule — Oral

Indications

essential hypertension obstructive sleep apnea syndrome